Literature DB >> 2452821

Hydrolysis of myelin basic protein in human myelin by terminal complement complexes.

P Vanguri1, M L Shin.   

Abstract

The participation of terminal complement complexes (TCC) in demyelination has been shown in rodent cerebellar cultures. Since TCC modulates activities of various membrane-associated enzymes and increases the level of cellular Ca2+ we investigated whether TCC could activate Ca2+-dependent neutral proteases in myelin that would lead to hydrolysis of myelin basic protein (BP). Addition of antibody and C7-deficient serum plus C7 to sealed myelin vesicles of two to six bilayers caused significant BP hydrolysis compared to the hydrolysis caused by antibody and C7-deficient serum. Significant hydrolysis occurred at the stage of C5b6,7 assembly, which increased in magnitude at the C5b6-8 stage. C5b6-9 formation did not enhance the effect of C5b6-8. BP hydrolysis by C5b6,7 did not require Ca2+ whereas the effect of C5b6-8/C5b6-9 was, in part, Ca2+-dependent. We postulated that TCC formation in myelin membranes causes activation of myelin-associated neutral proteases with subsequent hydrolysis of BP as a consequence of complement peptide insertion and channel formation. Such processes may alter the structure of myelin and augment the action of other inflammatory cells and their products in demyelinating diseases that could ultimately lead to the loss of myelin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2452821

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  A role for complement in phagocytosis of myelin.

Authors:  B A DeJong; M E Smith
Journal:  Neurochem Res       Date:  1997-04       Impact factor: 3.996

Review 2.  Membrane signaling by complement C5b-9, the membrane attack complex.

Authors:  A Nicholson-Weller; J A Halperin
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 3.  Membrane attack by complement: the assembly and biology of terminal complement complexes.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Snehal Patel; Richard Trippe; Violeta Rus; Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

4.  Genetic regulation of microglia activation, complement expression, and neurodegeneration in a rat model of traumatic brain injury.

Authors:  Bo-Michael Bellander; Olle Lidman; Marcus Ohlsson; Britt Meijer; Fredrik Piehl; Mikael Svensson
Journal:  Exp Brain Res       Date:  2010-07-03       Impact factor: 1.972

5.  Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis.

Authors:  Susanna H Weerth; Horea Rus; Moon L Shin; Cedric S Raine
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

Review 6.  Phagocytosis of myelin in demyelinative disease: a review.

Authors:  M E Smith
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

7.  Complement C5 regulates the expression of insulin-like growth factor binding proteins in chronic experimental allergic encephalomyelitis.

Authors:  Cornelia Cudrici; Takahiro Ito; Ekaterina Zafranskaia; Susanna Weerth; Violeta Rus; Hegang Chen; Florin Niculescu; Katerina Soloviova; Cosmin Tegla; Adrian Gherman; Cedric S Raine; Moon L Shin; Horea Rus
Journal:  J Neuroimmunol       Date:  2008-10-15       Impact factor: 3.478

8.  Complement C1q and C3 mRNA expression in the frontal cortex of Alzheimer's patients.

Authors:  B Fischer; H Schmoll; P Riederer; J Bauer; D Platt; A Popa-Wagner
Journal:  J Mol Med (Berl)       Date:  1995-09       Impact factor: 4.599

9.  Reversible injury of cultured rat oligodendrocytes by complement.

Authors:  N J Scolding; W A Houston; B P Morgan; A K Campbell; D A Compston
Journal:  Immunology       Date:  1989-08       Impact factor: 7.397

10.  Vacuolar myelopathy with multinucleated giant cells in the acquired immune deficiency syndrome (AIDS). Light and electron microscopic distribution of human immunodeficiency virus (HIV) antigens.

Authors:  H Maier; H Budka; H Lassmann; P Pohl
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.